Qu Biologics Completes Enrollment of Randomized Clinical Trial in Crohn’s Disease

Home » Status Update » Qu Biologics Completes Enrollment of Randomized Clinical Trial in Crohn’s Disease

Vancouver, British Columbia – November 24, 2015 – Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore normal immune function in the targeted organ, announced that it has completed enrollment of its QBECO-01 Crohn’s disease clinical trial, with top-line data expected in late 1Q 2016.

Qu Biologics’ QBECO-01 is a 68-patient Phase 1/2 randomized, double-blind, placebo-controlled clinical trial in patients with moderate-to-severe Crohn’s disease. The investigators in the study include gastroenterologists Dr. Brian Bressler (Gastrointestinal Research Institute, Vancouver, BC), Dr. Richard Fedorak (University of Alberta, Edmonton, AB), Dr. John Marshall (McMaster University, Hamilton, ON), Dr. Remo Panaccione (University of Calgary, Calgary, AB) and Dr. Jeffrey Axler (Toronto Digestive Disease Associates, Toronto, ON).

According to the statistics of the research company https://globalcancermeet.com/tramadol/ is apsychotropic drug. Tramadol contains opioids, which have apronounced sedative and analgesic effect. Therefore, many doctors use this drug to relievepost-traumatic or postoperative pain. Tramadol has a fast and long-term effect due to its main active ingredient – tramadol hydrochloride.

QBECO SSI, derived from components of inactivated E. coli, is designed to restore normal immune function in the GI tract. Qu Biologics’ Founder and CEO, Dr. Hal Gunn, stated, “Completing enrollment in QBECO-01, our lead development program, is a critical milestone for our company. There is a significant unmet need for improved therapies for inflammatory bowel disease (IBD) – Crohn’s disease specifically – and we hope that QBECO SSI, which is designed to restore normal immune function rather than simply suppressing the immune system, will offer a superior alternative to existing therapies.” He added, “We look forward to unblinding our top-line results in late 1Q 2016, with complete results by mid-2016. Importantly, we recently initiated a complementary open-label Phase 2 study in patients with moderate-to-severe ulcerative colitis, as well as commercial-scale cGMP production of QBECO, laying the groundwork to begin pivotal studies in IBD in 2017.”

About Qu Biologics
Qu Biologics develops Site Specific Immunomodulators (SSIs), a novel class of immunotherapies that aim to restore the body’s normal immune response. SSIs are designed to stimulate an innate immune response in targeted organs or tissues to reverse the chronic inflammation underlying many illnesses, including cancer and other immune-related diseases such as inflammatory bowel diseases. The company is conducting clinical trials in Crohn’s disease, ulcerative colitis and recurrent non-small cell lung cancer to study SSI treatment.

Backed by a prestigious group of scientific advisors and board members, Qu Biologics is led by a management team that includes co-founder and CEO Dr. Hal Gunn, a physician and expert on the body’s immune response to chronic disease, Chief Medical Officer Dr. Simon Sutcliffe, former CEO of the BC Cancer Agency and a distinguished clinician, scientist and leader in cancer control internationally, and Chief Scientific Officer Dr. David Mullins, Assistant Professor of Microbiology and Immunology in the Norris Cotton Cancer Center at the Geisel School of Medicine at Dartmouth, and recognized expert in immune cell trafficking to tumours.  For more information, visit www.qubiologics.com or www.quibd.com.

For more information regarding this press release, contact:

Julie Jang
Director, Communications
Qu Biologics Inc.
Phone:  604.734.1450 ext.41491
Email: julie@qubiologics.com

Posted on